Physician profile
Jonathan Keeling
NPI 1770605172
$13,101.24
in general payments reported to CMS, 2019-2025
30 companies · $2,307 in 2025
The $2,307 reported for 2025 was more than what 79% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,652 · 2020: $940 · 2021: $1,247 · 2022: $2,304 · 2023: $2,448 · 2024: $2,203 · 2025: $2,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,330 · Education: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,330.28 |
| Education | $627.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,595.23 | 2019-2025 | |
| Janssen Biotech, INC. | $1,805.98 | 2019-2025 | Tremfya |
| Amgen INC. | $1,138.11 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $1,130.01 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $1,119.64 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $1,027.43 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $642.49 | 2019-2025 | |
| Incyte Corporation | $549.02 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $544.58 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $440.49 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $394.63 | 2022-2025 | Sotyktu |
| Ucb, INC. | $289.37 | 2019-2025 | Bimzelx |
| Arcutis Biotherapeutics, INC. | $255.47 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $197.68 | 2019-2025 | Dupixent |
| Dermavant Sciences, INC. | $146.44 | 2023-2024 | Vtama |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $119.79 | 2024-2025 | Aklief, Nemluvio |
| Almirall LLC | $96.18 | 2022-2025 | Klisyri |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $86.94 | 2019-2020 | |
| Genentech USA, INC. | $79.76 | 2019 | |
| Celgene Corporation | $72.30 | 2019 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Botanix Sb INC | $64.85 | 2025 | Sofdra |
| Epi Health, LLC | $49.32 | 2019 | |
| Organon LLC | $43.78 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.58 | 2023 | Cyltezo |
| Dermira, INC. | $27.84 | 2019 | |
| Janssen Scientific Affairs, LLC | $27.78 | 2020 | |
| Verrica Pharmaceuticals INC. | $20.00 | 2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $19.33 | 2019 | |
| Fresenius Kabi USA, LLC | $13.22 | 2023 | Idacio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Keeling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.